Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
Subspace-Guided Semantic and Topological Invariant Registration for Annotation-Free Ultrasound Plane Quality Control
arXiv:2605.25396v1 Announce Type: cross Abstract: Reliable quality control (QC) of ultrasound images is essential for both real-time acquisition guidance and retrospective clinical audit, yet existing approaches rely heavily on per-plane annotations, or employ pseudo-labeling prone to systematic bias under spatial deformations inherent in clinical acquisition. We present STRIQ, a registration-driven framework that recasts annotation-free US plane quality control as a subspace-guided consistency
-
cs.AI, q-bio.NC updates on arXiv.org
-
Anatomy-Anchored Self-Supervision: Distilling Vision Foundation Models for Invariant Ultrasound Representation
arXiv:2605.25402v1 Announce Type: cross Abstract: Self-supervised pre-training paradigm has gained increasing prominence for learning transferable representations in medical imaging, yet existing methods for ultrasound (US) images operate at the image or frame level, overlooking the anatomical context for clinical-aligned representation learning. In this work, we propose an anatomy-anchored ultrasound self-supervision framework ANAUS that shifts representation learning from generic visual regio
Anatomy-Anchored Self-Supervision: Distilling Vision Foundation Models for Invariant Ultrasound Representation
-
cs.AI, q-bio.NC updates on arXiv.org
-
SentGraph: Hierarchical Sentence Graph for Multi-hop Retrieval-Augmented Question Answering
arXiv:2601.03014v3 Announce Type: replace-cross Abstract: Traditional Retrieval-Augmented Generation (RAG) effectively supports single-hop question answering with large language models but faces significant limitations in multi-hop question answering tasks, which require combining evidence from multiple documents. Existing chunk-based retrieval often provides irrelevant and logically incoherent context, leading to incomplete evidence chains and incorrect reasoning during answer generation. To a
SentGraph: Hierarchical Sentence Graph for Multi-hop Retrieval-Augmented Question Answering
-
Nature Biotechnology - Issue - nature.com science feeds
-
A framework for building a synthetic cell from the SynCell Asia Initiative
Nature Biotechnology, Published online: 26 May 2026; doi:10.1038/s41587-026-03153-wBuilding a living cell from scratch requires overcoming a bottleneck that has remained unresolved despite decades of progress: orchestrating the spatiotemporal integration of core functional modules. To tackle this barrier, the SynCell Asia Initiative outlines a strategy for developing core functional modules followed by their systems-level integration through the establishment of a centralized, artificial intelli
A framework for building a synthetic cell from the SynCell Asia Initiative
Nature Biotechnology, Published online: 26 May 2026; doi:10.1038/s41587-026-03153-w
Building a living cell from scratch requires overcoming a bottleneck that has remained unresolved despite decades of progress: orchestrating the spatiotemporal integration of core functional modules. To tackle this barrier, the SynCell Asia Initiative outlines a strategy for developing core functional modules followed by their systems-level integration through the establishment of a centralized, artificial intelligence (AI)-driven biofoundry.-
MRD
-
Liquid Biopsy in Modern Oncology: Advances, Challenges, and Future Perspectives in Early Cancer Detection, Minimal Residual Disease, and Dynamic Patient Monitoring
Curr Oncol Rep. 2026 May 23;28(1):59. doi: 10.1007/s11912-026-01799-y.ABSTRACTPURPOSE OF REVIEW: Liquid biopsy has emerged as a minimally invasive approach to overcome the limitations of tissue biopsy in oncology. This review aims to synthesize recent advances in its clinical applications, particularly in early cancer detection, therapeutic monitoring, and minimal residual disease (MRD), while discussing current challenges, regulatory perspectives, and future directions.RECENT FINDINGS: Circulat
Liquid Biopsy in Modern Oncology: Advances, Challenges, and Future Perspectives in Early Cancer Detection, Minimal Residual Disease, and Dynamic Patient Monitoring
Curr Oncol Rep. 2026 May 23;28(1):59. doi: 10.1007/s11912-026-01799-y.
ABSTRACT
PURPOSE OF REVIEW: Liquid biopsy has emerged as a minimally invasive approach to overcome the limitations of tissue biopsy in oncology. This review aims to synthesize recent advances in its clinical applications, particularly in early cancer detection, therapeutic monitoring, and minimal residual disease (MRD), while discussing current challenges, regulatory perspectives, and future directions.
RECENT FINDINGS: Circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles, and epigenetic markers are the most extensively studied biomarkers, in which clinical trials such as TRACERx and DYNAMIC have demonstrated that ctDNA monitoring enables earlier detection of recurrence and guides adjuvant therapy decisions more precisely than standard imaging. Commercially validated assays, including Guardant360 CDx, FoundationOne Liquid CDx, and Epi proColon, have received regulatory approval, reflecting growing clinical adoption; however, limitations persist, including reduced sensitivity in low-tumor burden settings, technical variability between platforms, and the risk of false positives from clonal hematopoiesis. Ongoing research highlights the promise of multi-omic approaches and the integration of artificial intelligence to improve sensitivity, capture tumor heterogeneity, and provide predictive insights into treatment response and resistance. Liquid biopsy represents a paradigm shift in precision oncology by enabling real-time, longitudinal tumor profiling. Although significant barriers remain, such as cost, accessibility, and lack of standardization, technological innovations and large-scale validation studies are paving the way for its routine clinical integration.
PMID:42176138 | DOI:10.1007/s11912-026-01799-y
-
(Multiomics OR Omics) AND (Pancreatic)
-
Microbiome in Gastrointestinal Tumors: Implications in Oncogenesis and Therapeutic Response : Microbiome in Gastrointestinal Tumors
Curr Oncol Rep. 2026 May 22;28(1):58. doi: 10.1007/s11912-026-01793-4.ABSTRACTPURPOSE OF REVIEW: To provide an updated overview of the role of the human microbiome in the initiation, progression, and therapeutic response of gastrointestinal tumors, emphasizing molecular, immunological, and metabolic mechanisms, as well as its potential as a target for novel therapeutic strategies.RECENT FINDINGS: Emerging evidence demonstrates that microbiome dysbiosis contributes to carcinogenesis across gastro
Microbiome in Gastrointestinal Tumors: Implications in Oncogenesis and Therapeutic Response : Microbiome in Gastrointestinal Tumors
Curr Oncol Rep. 2026 May 22;28(1):58. doi: 10.1007/s11912-026-01793-4.
ABSTRACT
PURPOSE OF REVIEW: To provide an updated overview of the role of the human microbiome in the initiation, progression, and therapeutic response of gastrointestinal tumors, emphasizing molecular, immunological, and metabolic mechanisms, as well as its potential as a target for novel therapeutic strategies.
RECENT FINDINGS: Emerging evidence demonstrates that microbiome dysbiosis contributes to carcinogenesis across gastrointestinal malignancies, including colorectal, gastric, hepatic, and pancreatic cancers. Microbial-derived metabolites, such as short-chain fatty acids and secondary bile acids, modulate key signaling pathways involved in cell proliferation, apoptosis, and genomic stability. In addition, the microbiome influences the tumor microenvironment and immune responses, shaping variability in treatment outcomes. Both preclinical and clinical studies have shown that microbiome composition affects the efficacy and toxicity of chemotherapy and immunotherapy. Notably, specific microbial signatures are being explored as non-invasive biomarkers for early detection and prognostic stratification, while microbiome modulation strategies, such as diet, probiotics, antibiotics, and fecal microbiota transplantation, have demonstrated potential to enhance therapeutic response. The bidirectional interaction between the microbiome and the host plays a central role in gastrointestinal tumorigenesis and treatment response. Although this field holds significant promise for precision oncology, its clinical translation remains limited by interindividual variability, methodological heterogeneity, and insufficient longitudinal evidence. Future efforts should focus on standardization, validation of microbiome-based biomarkers, and integration of multi-omics and artificial intelligence approaches to enable clinically actionable applications.
PMID:42171841 | DOI:10.1007/s11912-026-01793-4
-
Omics in Gastric
-
Microbiome in Gastrointestinal Tumors: Implications in Oncogenesis and Therapeutic Response : Microbiome in Gastrointestinal Tumors
Curr Oncol Rep. 2026 May 22;28(1):58. doi: 10.1007/s11912-026-01793-4.ABSTRACTPURPOSE OF REVIEW: To provide an updated overview of the role of the human microbiome in the initiation, progression, and therapeutic response of gastrointestinal tumors, emphasizing molecular, immunological, and metabolic mechanisms, as well as its potential as a target for novel therapeutic strategies.RECENT FINDINGS: Emerging evidence demonstrates that microbiome dysbiosis contributes to carcinogenesis across gastro
Microbiome in Gastrointestinal Tumors: Implications in Oncogenesis and Therapeutic Response : Microbiome in Gastrointestinal Tumors
Curr Oncol Rep. 2026 May 22;28(1):58. doi: 10.1007/s11912-026-01793-4.
ABSTRACT
PURPOSE OF REVIEW: To provide an updated overview of the role of the human microbiome in the initiation, progression, and therapeutic response of gastrointestinal tumors, emphasizing molecular, immunological, and metabolic mechanisms, as well as its potential as a target for novel therapeutic strategies.
RECENT FINDINGS: Emerging evidence demonstrates that microbiome dysbiosis contributes to carcinogenesis across gastrointestinal malignancies, including colorectal, gastric, hepatic, and pancreatic cancers. Microbial-derived metabolites, such as short-chain fatty acids and secondary bile acids, modulate key signaling pathways involved in cell proliferation, apoptosis, and genomic stability. In addition, the microbiome influences the tumor microenvironment and immune responses, shaping variability in treatment outcomes. Both preclinical and clinical studies have shown that microbiome composition affects the efficacy and toxicity of chemotherapy and immunotherapy. Notably, specific microbial signatures are being explored as non-invasive biomarkers for early detection and prognostic stratification, while microbiome modulation strategies, such as diet, probiotics, antibiotics, and fecal microbiota transplantation, have demonstrated potential to enhance therapeutic response. The bidirectional interaction between the microbiome and the host plays a central role in gastrointestinal tumorigenesis and treatment response. Although this field holds significant promise for precision oncology, its clinical translation remains limited by interindividual variability, methodological heterogeneity, and insufficient longitudinal evidence. Future efforts should focus on standardization, validation of microbiome-based biomarkers, and integration of multi-omics and artificial intelligence approaches to enable clinically actionable applications.
PMID:42171841 | DOI:10.1007/s11912-026-01793-4
-
Nature - Issue - nature.com science feeds
-
A pathogen lncRNA secreted into rice sequesters a host miRNA for virulence
Nature, Published online: 20 May 2026; doi:10.1038/s41586-026-10572-xA fungal long non-coding RNA from Magnaporthe oryzae translocates into rice cells to sequester a host microRNA that normally represses PKR1, a negative immunity regulator, thereby facilitating infection and revealing a widespread RNA-based pathogen–host interaction mechanism.
A pathogen lncRNA secreted into rice sequesters a host miRNA for virulence
Nature, Published online: 20 May 2026; doi:10.1038/s41586-026-10572-x
A fungal long non-coding RNA from Magnaporthe oryzae translocates into rice cells to sequester a host microRNA that normally represses PKR1, a negative immunity regulator, thereby facilitating infection and revealing a widespread RNA-based pathogen–host interaction mechanism.-
Oncogenesis - nature.com science feeds
-
Ubiquitin-specific protease 11 suppresses cuproptosis in colorectal cancer by regulating the ubiquitination and stability of ISCU
Oncogenesis, Published online: 08 May 2026; doi:10.1038/s41389-026-00621-5Ubiquitin-specific protease 11 suppresses cuproptosis in colorectal cancer by regulating the ubiquitination and stability of ISCU
Ubiquitin-specific protease 11 suppresses cuproptosis in colorectal cancer by regulating the ubiquitination and stability of ISCU
Oncogenesis, Published online: 08 May 2026; doi:10.1038/s41389-026-00621-5
Ubiquitin-specific protease 11 suppresses cuproptosis in colorectal cancer by regulating the ubiquitination and stability of ISCU-
Omics in Gastric
-
Multi-omics integration and Mendelian randomization reveal the mechanisms and experimental validation of curcumin targeting the RXRA-PI3K/AKT axis to enhance cisplatin sensitivity in gastric cancer
Front Oncol. 2026 Apr 15;16:1791971. doi: 10.3389/fonc.2026.1791971. eCollection 2026.ABSTRACTOBJECTIVE: This study aimed to integrate multi-omics analyses with genetic causal inference to identify key genes associated with cisplatin resistance in gastric cancer and to evaluate the potential mechanism by which curcumin enhances cisplatin sensitivity through relevant pathways.METHODS: Cisplatin resistance-related transcriptomic datasets(GSE14210 and GSE31811) and a gastric cancer single-cell tran
Multi-omics integration and Mendelian randomization reveal the mechanisms and experimental validation of curcumin targeting the RXRA-PI3K/AKT axis to enhance cisplatin sensitivity in gastric cancer
Front Oncol. 2026 Apr 15;16:1791971. doi: 10.3389/fonc.2026.1791971. eCollection 2026.
ABSTRACT
OBJECTIVE: This study aimed to integrate multi-omics analyses with genetic causal inference to identify key genes associated with cisplatin resistance in gastric cancer and to evaluate the potential mechanism by which curcumin enhances cisplatin sensitivity through relevant pathways.
METHODS: Cisplatin resistance-related transcriptomic datasets(GSE14210 and GSE31811) and a gastric cancer single-cell transcriptomic dataset (GSE183904) were obtained from the Gene Expression Omnibus(GEO)database. Differential expression analysis was performed to identify resistance-associated differentially expressed genes(DEGs),followed by GO and KEGG enrichment analyses. Putative curcumin targets were collected and intersected with DEGs to obtain candidate genes. Mendelian randomization (MR) analysis was conducted using the TwoSampleMR framework to evaluate the genetic association between RXRA expression and gastric cancer risk, with robustness and sensitivity analyses based on multiple MR methods. RXRA expression was further evaluated, along with pathway activity assessment using GSEA and GSVA, and molecular docking was performed to explore the potential binding of curcumin to RXRA. In vitro experiments were performed using the cisplatin-resistant gastric cancer cell lineNCI-N87/DDP. Drug effects and chemosensitization under combination treatment were assessed by CCK-8 assays, synergy was evaluated using the combination index(CI),and changes in key proteins in thePI3K/AKT pathway were measured by Western blotting.
RESULTS: A total of 595 DEGs associated with cisplatin resistance were identified. Functional enrichment analyses indicated that these DEGs were mainly involved in extracellular matrix remodeling and adhesion, secretion and vesicular transport, and signaling pathways including PI3K-Akt.The intersection of curcumin targets with DEGs highlighted RXRA as a key candidate gene. MR results indicated that genetically predicted increased RXRA expression was significantly associated with elevated gastric cancer risk (OR = 4.216,95%CI:1.201-14.797,P=0.025). GSEA and GSVA suggested that high RXRA expression was associated with altered activity of pathways related to lysosome, proteasome, oxidative phosphorylation, and the pentose phosphate pathway. Single-cell analysis indicated that RXRA was mainly expressed in tissue stem cells and fibroblasts. Molecular docking predicted a feasible interaction between curcumin and RXRA. In vitro experiments demonstrated that curcumin inhibited the viability of resistant cells and showed a synergistic trend when combined with cisplatin. Western blotting revealed decreased p-PI3K and p-AKT levels following curcumin treatment, supporting an inhibitory effect on the PI3K/AKT pathway.
CONCLUSION: These findings highlight RXRA as a candidate gene associated with cisplatin resistance-related programs in gastric cancer. Curcumin may enhance cisplatin sensitivity by influencing RXRA-associated transcriptional networks and suppressing PI3K/AKT signaling. This study provides new candidate targets and experimental evidence for mechanistic investigation and combination treatment strategies to overcome cisplatin resistance in gastric cancer.
PMID:42063729 | PMC:PMC13124633 | DOI:10.3389/fonc.2026.1791971
-
Cell
-
Transplantation of encapsulated mitochondria alleviates dysfunction in mitochondrial and Parkinson’s disease models
A mitochondrial transplantation approach rescues mitochondrial deficiency and prevents mitochondrial DNA depletion syndrome, Leigh syndrome, and Parkinson’s disease in cellular and mouse models.
Transplantation of encapsulated mitochondria alleviates dysfunction in mitochondrial and Parkinson’s disease models
-
Cell
-
Respiratory viral infections prime accelerated lung cancer growth
Severe COVID-19 is associated with an increased subsequent risk of lung cancer. Viral pneumonia induces durable lung epigenetic imprinting that promotes tumor-supportive neutrophils and impairs T cell immunity, which is reversible with combined CXCR2 inhibition and PD-L1 blockade.